Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Rare Diseases

Sarcoma

Sarcoma, Ewing

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Osteosarcoma

Neoplasms, Bone Tissue

Neoplasms, Connective Tissue

Soft Tissue Sarcoma

Ewing Sarcoma

This cohort include patients affected by Ewing Sarcoma of bone, referred to participating Institutions.

This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments

Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)

Alexia Bertuzzi, MD

Maurizio Mascarin, MD

Sandra Aliberti, MD

Francesco De Leonardis, MD

Arcangelo Prete, MD

Toni Ibrahim, MD

Angela Tamburini, MD

Carla Manzitti, MD

Rossella Bertulli, MD

Roberto Luksch, MD

Massimo Eraldo Abate, MD

Gianni Bisogno, MD

Paolo D'Angelo, MD

Patrizia Bertolini, MD

Luca Coccoli, MD

Giuseppe Maria Milano, MD

Virginia Ferraresi, MD

Franca Fagioli, MD

Marco Rabusin, MD

Observational prospective trial aimed to collect the collect demographic, clinical, surgical, pathological and molecular characteristics and treatment from patients affected by skeletal Ewing Sarcoma

The Ewing sarcoma treatment is based on chemotherapy, surgery and radiotherapy. Chemotherapy, performed with a combination of several drugs, is given as primary treatment before surgery.

Surgical intervention must be performed in all cases in which it is possible to obtain an excision with free margins and with acceptable functional deficits. However, when, after surgery in case of incomplete resection, post-operative radiotherapy is used, in order to reduce the risk of local recurrence as much as possible.

Subsequently in the local treatment, a phase of maintenance chemotherapy is foreseen, the intensity of which is modulated according to the response to induction therapy.

The treatments are carried out with different programs for patients with localized disease or metastatic disease and derive from clinical trials carried out in the last 30 years.

These results are the result of national and international prospective trials which, precisely due to the rarity of the disease, took many years to execute, and it is significant to know that randomized studies were in very limited numbers, as almost all the studies were represented by studies of uncontrolled phase II Improving treatments requires the expansion of knowledge on the biological behavior of this tumor and the acquisition of as much information as possible deriving from clinical experience.

For this reason, pending the definition of a new prospective randomized trial, which will take time (approximately two years) to be made operational, it is considered useful from a scientific point of view to prospectively collect data relating to new cases of Ewing's sarcoma 'bone.

Observational Study on Skeletal Ewing's Sarcoma

Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis

Onset of any event (an event is the defined as disease recurrence, death for disease or any other cause)

Time elapsed for the diagnosis to the death for any cause

Number of Participants of age \>21 years with Treatment-Related Adverse Events as Assessed by CTCAE v5.0,

Collection of clinical pathological characteristics at disease presentation/diagnosis

Italian Sarcoma Group

Spots Global Cancer Trial Database for treatment of ewings sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)